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Abstract 
The objective of the present study was to determine whether a mitochondria-targeted vitamin E derivative 
(MitoVit E) would affect certain mitochondrial parameters, as well as systemic oxidative stress. A total of 
sixty-four mice were fed a high-fat (HF) diet for 5 weeks. They were then switched to either a low-fat (LF) 
or a medium-fat (MF) diet, and administered orally with MitoVit E (40 mg MitoVit E/kg body weight) or 
drug vehicle (10 % (v/v) ethanol in 0·9 % (w/v) NaCl solution), every other day for 5 weeks. Mitochondrial 
ATP and H2O2 production rates in both the liver and the gastrocnemius were not affected by MitoVit E 
administration in either LF or MF diet-fed mice. However, the number and average size of the 
subsarcolemmal mitochondria, but not the intermyofibrillar mitochondria, from the soleus muscle were 
significantly higher in the MF group receiving MitoVit E (MF-E) than in the MF group receiving vehicle only 
(MF-C). After the mice were switched from the HF diet to the four dietary treatments (LF-C, LF-E, MF-C 
and MF-E), the decrease in urinary isoprostane concentration was significantly greater in the LF-E group 
than in the other three groups during the whole study (weeks 6–10). In addition, MitoVit E significantly 
increased plasma superoxide dismutase (SOD) activity in the MF diet-fed group without affecting plasma 
glutathione peroxidase activity or H2O2 levels. Overall, these data suggest that MitoVit E affects 
subsarcolemmal mitochondrial density and systemic oxidative stress parameters such as plasma SOD 
activity and urinary isoprostane concentration. 
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Abstract
The objective of the present study was to determine whether a mitochondria-targeted vitamin E derivative (MitoVit E) would affect certain
mitochondrial parameters, as well as systemic oxidative stress. A total of sixty-four mice were fed a high-fat (HF) diet for 5 weeks. They
were then switched to either a low-fat (LF) or a medium-fat (MF) diet, and administered orally with MitoVit E (40 mg MitoVit E/kg body
weight) or drug vehicle (10 % (v/v) ethanol in 0·9 % (w/v) NaCl solution), every other day for 5 weeks. Mitochondrial ATP and H2O2 pro-
duction rates in both the liver and the gastrocnemius were not affected by MitoVit E administration in either LF or MF diet-fed mice.
However, the number and average size of the subsarcolemmal mitochondria, but not the intermyofibrillar mitochondria, from the
soleus muscle were significantly higher in the MF group receiving MitoVit E (MF-E) than in the MF group receiving vehicle only
(MF-C). After the mice were switched from the HF diet to the four dietary treatments (LF-C, LF-E, MF-C and MF-E), the decrease in urinary
isoprostane concentration was significantly greater in the LF-E group than in the other three groups during the whole study (weeks 6–10).
In addition, MitoVit E significantly increased plasma superoxide dismutase (SOD) activity in the MF diet-fed group without affecting plasma
glutathione peroxidase activity or H2O2 levels. Overall, these data suggest that MitoVit E affects subsarcolemmal mitochondrial density and
systemic oxidative stress parameters such as plasma SOD activity and urinary isoprostane concentration.
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Mitochondria are often referred to as the powerhouse of the
cell because they consume nearly 90 % of cells’ oxygen to sup-
port oxidative phosphorylation for the synthesis of ATP, the
energy currency used for a variety of metabolic reactions.
Mitochondrial ATP production occurs when electrons are
passed along a series of molecular complexes in the inner
mitochondrial membrane known as the electron transport
chain. The energy released by the flow of electrons through
the electron transport chain is used to transfer protons
across the inner mitochondrial membrane, creating a large
mitochondrial membrane potential, which is used to drive
ATP synthesis as protons re-enter the mitochondrial matrix
through the F0F1 ATP synthase
(1). Ideally, the transfer of elec-
trons across the electron transport chain should result in the
four-electron reduction of molecular oxygen (O2) to water
(H2O). However, this is not always the case.
During the transfer of electrons along the electron transport
chain, single electrons sometimes escape and result in a single
electron reduction of molecular oxygen to form a superoxide
anion (O†22 )
(2). It is estimated that as much as 1 % of all
oxygen consumed may result in the formation of reactive
oxygen species (ROS) such as O†22 , with the vast majority of
ROS being generated in the mitochondria(3), supporting the
prevailing opinion that the mitochondria are the major site
† Present address: B180 Medical Laboratories, Free Radical and Radiation Biology Program, University of Iowa, Iowa City, IA 52 242-1181, USA.
‡ Present address: Center for Medicinal Chemistry, Korea Research Institute of Chemical Technology, Daejeon 305-600, Republic of Korea.
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of ROS production in the cell and therefore the prime targets
for oxidative damage(4). Superoxide may spontaneously
dismute, or the dismutation may be catalysed by superoxide
dismutase (SOD), forming H2O2. This can cause oxidative
damage to the surrounding biomolecules, as, in the presence
of ferrous Fe, H2O2 may react to form the highly reactive
hydroxyl radical, via Fenton chemistry.
In order to combat the effects of ROS, aerobic organisms
have developed an extensive antioxidant defence system,
which include both non-enzymatic and enzymatic antioxi-
dants. Enzymatic antioxidants include SOD, glutathione
peroxidase (GPx) and catalase(5), whereas non-enzymatic
antioxidants are represented by vitamin C, vitamin E, thiol
antioxidants (glutathione and lipoic acid) and other antioxi-
dants(6). However, when these ROS are chronically produced
at high rates, they may overwhelm non-enzymatic and enzy-
matic antioxidant systems. As a result, ROS could then cause
deleterious effects by inducing the irreversible oxidation of
their principal targets such as DNA, lipids and proteins(7),
leading to oxidative damage and cell death.
Oxidative damage to the mitochondria has been proposed to
cause a wide range of metabolic disorders including Parkinson’s
disease(8,9), Huntington’s disease(10), Alzheimer’s disease(11,12),
diabetes(13), obesity(14), fatty liver(15) and ageing(16,17). For the
last three decades, antioxidant therapy has been intensively
studied to prevent or treat these oxidative stress-associated
diseases. Although antioxidants such as vitamin E, ubiquinol
and N-acetylcysteine have previously been reported to decrease
mitochondrial ROS concentrations and consequently alleviate
mitochondrial oxidative damage(18–20), their effectiveness still
seems to be largely limited by their poor capacity to accumulate
specifically within the mitochondria.
Recently, Murphy and co-workers(21,22) developed a series
of mitochondria-targeted antioxidants by conjugation with
triphenylphosphonium cations, which can permeate lipid
bilayers easily and accumulate 100- to 1000-fold within the
mitochondria. One of these mitochondria-targeted antioxi-
dants is a mitochondria-targeted vitamin E derivative (MitoVit
E), which has been tested in a wide range of mitochondrial
and cell models. Indeed, it has been shown to mitigate
ethanol-induced suppression of antioxidant defence systems in
cerebellar granule cells(23), inhibit peroxide-induced apoptosis
in endothelial cells(24) and prevent cell death in Friedreich’s
ataxia fibroblasts(25). However, to our knowledge, the effect
of MitoVit E on mitochondrial alterations and systemic oxi-
dative stress has never been studied in vivo. In order to inves-
tigate this further, we investigated the effects of MitoVit E on
mitochondrial ATP and H2O2 production rates, mitochondrial
size and number, urinary isoprostane concentration, and
some plasma redox biomarkers in C57BL/6 mice.
Materials and methods
Chemicals
MitoVit E was synthesised with the starting material benzo-
pyran-6-ol acetate, which was prepared in one step from com-
mercially available chemicals as reported by Ichikawa &
Kato(26). Benzopyran-6-ol acetate was oxidised using ozone
in methylene chloride–methanol at 2788C. The resulting sol-
ution was purged with Ar to remove excess ozone and then
treated directly with sodium borohydride to produce an alco-
hol similar to that in the scientific literature(26,27). The alcohol
was converted to MitoVit E as reported by Grisar et al.(28).
Briefly, the alcohol was treated with iodine, triphenylpho-
sphine and imidazole in methylene chloride at 08C for 3 h to
obtain a 92 % iodide yield. The iodide was treated with triphe-
nylphosphine in acetonitrile at reflux for 11 h to produce the
phosphonium salt as a crystalline solid in quantitative yield.
The product of MitoVit E was .95 % pure as evidenced by
TLC and NMR.
All the other chemicals used in the present study were
obtained from Sigma-Aldrich (St Louis, MO, USA), unless
otherwise stated.
Animals and study design
A total of sixty-four 7-week-old C57BL/6 male mice (Jackson
Laboratory, Bar Harbor, ME, USA) were divided into four
blocks and arrived at four different times. Mice were housed
one per cage in a temperature-controlled (18–228C) and
light-controlled environment with a 12 h light–12 h dark
cycle. Mice were fed a high-fat (HF) diet for 5 weeks and
then switched to either a low-fat (LF) diet or a medium-fat
(MF) diet, and administered orally with MitoVit E (40 mg MitoVit
E/kg body weight) or drug vehicle (10 % (v/v) ethanol in 0·9 %
(w/v) NaCl solution), every other day for 5 weeks. Detailed
compositions of the HF, MF and LF diets are provided in
Table S1 of the supplementary material (available online at
http://www.journals.cambridge.org/bjn). All mice in the four
groups (LF group receiving drug vehicle, LF-C; LF group receiv-
ing MitoVit E, LF-E; MF group receiving drug vehicle, MF-C; MF
group receiving MitoVit E, MF-E) had unrestricted access to
feed and water. During the study, urine was collected for iso-
prostane and creatinine assays. At the end of the study, all
mice were killed by exposure to CO2 in a gas chamber. Blood
was collected by cardiac puncture for biochemical assays in
the plasma. The gastrocnemius and liver from eight mice of
each group were rapidly excised for mitochondrial isolation
and subsequent measurements of ATP and H2O2 production
rates in the mitochondria. The soleus muscles from two mice
of each group were used in transmission electron microscopy
for quantification of mitochondrial number and average size.
Institutional and national guidelines for the care and use of
animals were followed, and all experimental procedures invol-
ving animals were approved by the Institutional Animal Care
and Use Committee of Iowa State University.
Mitochondrial preparation from the liver and skeletal
muscle
Liver mitochondria were isolated at 48C, as described previously
by Cawthon et al.(29), with some modifications. Briefly, liver
tissue (0·5 g) was homogenised using a Potter–Elvehjem glass
homogeniser (Omni International, Kennesaw, GA, USA) in
10 ml iced extraction buffer (10 mM-HEPES, 200 mM-mannitol,
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70 mM-sucrose, 1 mM-ethylene glycol tetra-acetic acid and
bovine serum albumin (2 g/l), pH 7·5). Homogenates were cen-
trifuged at 600 g for 8 min, and the supernatants were filtered
through a double layer of cheesecloth followed by centrifu-
gation at 11 000 g for 12 min. The pellet was resuspended in
20 ml extraction buffer without bovine serum albumin and
centrifuged at 600g for 8 min. The supernatants were centri-
fuged at 11 000g for 12 min to get the final mitochondrial pellets
for subsequent analyses.
Skeletal muscle mitochondria were isolated at 48C, as
described previously by Chappell & Perry(30), with slight
modifications. The gastrocnemius was minced with scissors
in Chappell–Perry Medium I (100 mM-KCl, 50 mM-Tris–HCl,
5 mM-MgCl2, 1 mM-EDTA and 1 mM-ATP, pH 7·2) and incubated
in 20 vol. of Chappell–Perry Medium I supplemented with
Nagarse (150 mg/l; Sigma-Aldrich) for 10 min. The muscles
were then homogenised at 48C with a Potter–Elvehjem glass
homogeniser (Omni International). After the homogenate
was centrifuged at 600g for 10 min, the supernatant was fil-
tered through a double layer of cheesecloth and centrifuged
at 14 000 g for 10 min. The pellets were resuspended in modi-
fied Chappell–Perry II buffer (100 mM-KCl, 50 mM-Tris–HCl,
1 mM-MgCl2, 0·2 mM-EDTA and 1 mM-ATP, pH 7·2) with 0·5 %
(w/v) bovine serum albumin and centrifuged at 7000 g for
10 min. The pellets were resuspended in modified Chappell–
Perry II buffer without bovine serum albumin and centrifuged
at 3500g for 10 min; this step was repeated twice. Mitochon-
drial pellets were used for subsequent analyses.
Determination of ATP and hydrogen peroxide production
rates in the mitochondria
ATP production rate was measured, as described previously
by Mansouri et al.(31). Reactions were conducted in ninety-
six-well microplates with a 100ml reaction system (25mM-Tricine,
5 mM-MgSO4, 0·1 mM-EDTA and 0·1 mM-NaN3, pH 7·8)
containing 100mg of mitochondrial protein, substrates
(1 mM-glutamate plus 1 mM-malate), ADP (0·025 mmol/l) and
luciferase reagent (Roche, Madison, WI, USA). Luminescence
was recorded by the Synergye 2 Multi-Mode microplate
reader (BioTek Instruments, Winooski, VT, USA) every 36 s
for a total of 6 min. The slope of increase within the linear
portion of the curve was used for the ATP production rate.
Mitochondrial H2O2 production rate was measured by using
Amplexe Red–horseradish peroxidase (N-acetyl-3,7-dihy-
droxyphenoxazine; Invitrogen, Carlsbad, CA, USA), as
described previously by Muller et al.(32). Sample reactions
were conducted in ninety-six-well microplates with a 100ml
reaction system (125 mM-KCl, 10 mM-HEPES, 2 mM-K2HPO4
and 5 mM-MgCl2) containing 40mg of mitochondrial protein,
substrate (9 mM-succinate), CuZnSOD (100 000 units/l),
Amplexe Red reagent (80mmol/l) and horseradish peroxidase
(1000 units/l). Fluorescence was recorded at an excitation
wavelength of 530 nm and an emission wavelength of
590 nm on the Synergye 2 Multi-Mode microplate reader
(BioTek Instruments) every 36 s for a total of 10 min. The
slope of increase within the linear portion of the curve was
used for the H2O2 production rate.
For the two aforementioned assays, sample blanks con-
tained all components in the reaction system except mito-
chondrial protein. The slopes of the increase in the blanks
were subtracted from the slopes of the increase in the
samples. The results for ATP and H2O2 production rates
were analysed by Gen5 (BioTek Instruments).
Measurement of mitochondrial size and number
Soleus muscle was excised from mice and immediately
immersed in a cold (48C) primary fixative consisting of 2 %
(w/v) glutaraldehyde and 2 % (w/v) paraformaldehyde in a
0·1 M-cacodylate buffer at pH 7·24. The muscle was sliced
into smaller pieces in the fixative and stored overnight at
48C. The pieces were washed in cold buffer (three times,
20 min each) and placed into 1 % (w/v) OsO4 in the same
buffer for 1 h. After this secondary fixation, the pieces were
washed several times in the buffer, placed into 2 % (w/v) aqu-
eous uranyl acetate for 1 h and dehydrated through an ethanol
series to pure ethanol and ultra-pure ethanol before infiltra-
tion with increasing concentrations of Embed 812 resin mix-
ture to pure resin mixture. Pieces were embedded in moulds
and polymerised at 608C for 24 h. The pieces were sectioned
(1mm thick) with glass knives using a Leica–Reichert ultrami-
crotome (www.leica.com) to determine orientation and
location. Thin sections (60–90 nm) thick were cut with a dia-
mond knife and placed on 200 mesh Cu grids. Images were
made using a JEOL 2100 TEM (www.jeol.com) set at a magni-
fication (4000 £ ) with a bar scale on each image. The images
were transferred into an SIS Analysis (Olympus, Münster,
Germany; www.soft-imaging.net) program that calculated
mitochondrial number and individual area.
Measurement of urinary isoprostane and creatinine
Urine samples were thawed at room temperature and vor-
texed vigorously before analysis. Urinary 8-iso-PGF2a was
determined using a commercially available ELISA kit from
Oxford Biomedical Research (Oxford, MI, USA). Internal con-
trols were run on every plate to adjust the plate differences.
Urinary creatinine was quantified with a commercial kit from
Cayman Chemical (Ann Arbor, MI, USA) using a method
based on the reaction of creatinine and alkaline picrate
according to the manufacturer’s instructions. Results of urinary
isoprostane were normalised by urinary creatinine.
Measurement of redox parameters in the plasma
Activities of plasma SOD and GPx were measured using kits
from Cayman Chemical. Plasma H2O2 concentration was
measured using an Amplex Red hydrogen peroxide assay kit
from Invitrogen.
Determination of protein concentration
Protein concentration was measured using the Bradford
method(33).
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Data were analysed by ANOVA using a general randomised
complete block design, with each of the four different arrival
times considered as a block. Block, diet, MitoVit E and their
interaction were the fixed effects in the model. SAS Proc
Mixed (SAS, 2005; SAS Institute, Cary, NC, USA) was used to
compute the ANOVA table, least-squares means and differ-
ences between the least-squares means. A block effect repre-
senting differences between the four blocks could be
attributed to many factors (e.g. four blocks of mice were
different, or assay reagents or set-ups in the four individual
experiments were different). The block effect is not discussed
in the present study, but it has to be ruled out for correctly
evaluating the effects of the MF diet and MitoVit E. Data are
presented as means with their standard errors. Differences
between groups were considered to be significant at P,0·05.
Results
Levels of urinary isoprostane and mouse body weight
before treatments
Isoprostanes are a unique series of PG-like compounds
formed in vivo from the free radical-catalysed peroxidation
of arachidonic acid independent of cyclo-oxygenase
enzymes(34). The quantification of plasma or urinary F2-iso-
prostanes has been regarded as one of the most accurate
methods to assess in vivo oxidant stress status when compared
with other biomarkers(35). Levels of urinary isoprostane
increased 6- and 7·5-fold, respectively, after 2 and 4 weeks
of HF feeding before either drug vehicle or MitoVit E admin-
istration (Fig. 1(a)). Body weight also increased significantly
(P,0·05) during this period (Fig. 1(b)).
Mitochondrial ATP and hydrogen peroxide production
rates
In both the liver and muscle, ATP and H2O2 production rates
were not affected by either MitoVit E administration or the MF
diet when succinate was used as the substrate (Table 1). ATP
production rate in the muscle mitochondria was almost as
twentyfold high as that in the liver mitochondria, whereas
H2O2 production rate in the liver mitochondria was as tenfold
high as that in the muscle mitochondria (Table 1).
Measurement of mitochondrial number and size
The number and average size of the intermyofibrillar mito-
chondria were not affected by MitoVit E treatment in either
LF or MF diet-fed mice (Table 2). However, the number and
average size of the subsarcolemmal mitochondria were four-
and twofold higher in MF-E mice than in MF-C mice, respect-
ively (P,0·05). Conversely, the number of intermyofibrillar
and subsarcolemmal mitochondria was significantly decreased
in the MF-C group compared with the LF-C group (Table 2).
In addition, there was a diet £ MitoVit E interaction effect for
the number of subsarcolemmal mitochondria (P¼0·035). The
representative transmission electron microscopic images of
subsarcolemmal and intermyofibrillar mitochondria from the
soleus muscle of LF-C, LF-E, MF-C and MF-E mice are
shown in Fig. 2, where arrows indicate mitochondria. Remark-
ably, in the MF-C group, very few intermyofibrillar mitochon-
dria were observed, and subsarcolemmal mitochondria had an
increased number of disarrayed cristae and a reduced electron
density of the matrix. By contrast, MitoVit E administration
increased the mitochondrial number and electron density in
MF diet-fed mice.
Measurement of urinary isoprostane after treatments
After 2 and 4 weeks of HF feeding, urinary isoprostane con-
centration increased four- and fivefold, respectively
(Fig. 1(a)). However, after the mice were switched from the
HF diet to either the LF or the MF diet with or without MitoVit
E, urinary isoprostane concentration decreased in the first
week (week 6) immediately (Table 3). The levels of the
decreased urinary isoprostane after the first week (week 6)
were maintained for the rest of the study (weeks 7–10) for
all four groups (Table 3). The administration of MitoVit E sig-
nificantly enhanced the decrease in urinary isoprostane in LF
diet-fed mice (LF-C v. LF-E) for the whole study, but not in
MF diet-fed mice (MF-C v. MF-E) except at week 6 (Table 3).
100(a)
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Fig. 1. (a) Urinary isoprostane concentration of mice in the first 4 weeks when fed a high-fat (HF) diet (n 48). Urinary isoprostane was normalised by urinary creati-
nine (mmol/mol creatinine). (b) Body weight of mice in the first 4 weeks when fed a HF diet (g/d, n 64). Values are means, with standard errors represented by ver-
tical bars. * Mean values were significantly different from those of week 0 (P,0·05).
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In addition, the decrease in urinary isoprostane was signifi-
cantly higher in the LF-E group than in the other three
groups during the whole study (weeks 6–10), indicating that
the combination of LF diet and MitoVit E administration is
most effective in decreasing systemic oxidative stress.
Measurement of redox parameters in the plasma
Plasma SOD activity was lower in the MF-C group than in the
LF-C group (P,0·05). Plasma GPx activity was also signifi-
cantly decreased in the MF-E group compared with the LF-E
group (Table 4). Concentrations of plasma H2O2 in the LF-C
and LF-E groups were significantly lower than in the MF-C
and MF-E groups, respectively (Table 4). A significant increase
in plasma SOD activity was observed in MF-E group when
compared with the MF-C group. In addition, there was a diet £
MitoVit E interaction effect for plasma SOD activity (P¼0·038).
Discussion
Our oxidative stress model was established by feeding mice a
HF diet for 5 weeks to induce higher oxidative stress, which
was indicated by the increase in urinary isoprostane
(Fig. 1(a)). Cumulative evidence strongly suggests that elev-
ated oxidative stress is associated with obesity develop-
ment(36–39). This suggestion has been confirmed by our
observations that urinary isoprostanes increased with
increased body weight during the first 4 weeks of HF feeding
(Fig. 1(a) and (b)).
Mitochondrial ATP production rate was not affected by
MitoVit E in either the liver or the gastrocnemius. This obser-
vation was confirmed by using different combinations of sub-
strates for measuring the mitochondrial ATP production rates,
such as glutamate plus malate in the present study, glutamate
plus malate plus palmitoyl-L-carnitine(40) and glutamate plus
malate plus palmitoyl-L-carnitine plus a-ketoglutarate (G
Mao, GA Kraus, I Kim, ME Spurlock, TB Bailey and DC
Beitz, unpublished results).
No effects of MitoVit E on mitochondrial H2O2 production
rate were observed in the present study when succinate was
used as the substrate. However, when glutamate plus malate
was used as the substrate, MitoVit E in the same study signifi-
cantly decreased the mitochondrial H2O2 production in the
liver but not in the muscle of MF diet-fed mice(40), indicating
that the effect of MitoVit E on scavenging mitochondria-
derived ROS might be substrate-dependent and thus
complex-dependent.
In addition, the capacity of MitoVit E in reducing the mito-
chondrial oxidative damage has been confirmed by our obser-
vation that it significantly reduced protein carbonyl in the liver
mitochondria of MF-E mice compared with MF-C mice(40),
which is consistent with the previous finding that MitoVit E
Table 1. ATP and hydrogen peroxide production rates in the liver and muscle mitochondria of low-fat diet-fed mice receiving drug vehicle (LF-C), low-
fat diet-fed mice receiving mitochondria-targeted vitamin E derivative (MitoVit E) (LF-E), medium-fat diet-fed mice receiving drug vehicle (MF-C) and
medium-fat diet-fed mice receiving MitoVit E (MF-E)
(Mean values with their standard errors for seven to eight mice per group)
LF-C LF-E MF-C MF-E ANOVA (P )*
Mean SEM Mean SEM Mean SEM Mean SEM Block Diet MitoVit E Diet £ MitoVit E
ATP production rate (nmol/min per mg protein)
Liver 0·360 0·050 0·350 0·048 0·320 0·026 0·390 0·029 0·977 0·976 0·419 0·333
Muscle 6·187 1·310 5·320 1·229 4·943 1·182 6·033 1·148 0·153 0·909 0·990 0·364
H2O2 production rate (nmol/min per mg protein)
Liver 0·146 0·011 0·138 0·046 0·166 0·016 0·152 0·012 0·226 0·173 0·349 0·816
Muscle 0·015 0·002 0·014 0·005 0·016 0·002 0·016 0·006 0·054 0·481 0·322 0·222
* Values of ANOVA (P ) are P values for block effect and main effects, such as diet, MitoVit E and interaction between diet and MitoVit E in the LF-C, LF-E, MF-C and MF-E groups.
Table 2. Mitochondrial number and average size in the soleus muscle of low-fat diet-fed mice receiving drug vehicle (LF-C), low-fat diet-fed mice
receiving mitochondria-targeted vitamin E derivative (MitoVit E) (LF-E), medium-fat diet-fed mice receiving drug vehicle (MF-C) and medium-fat diet-fed
mice receiving MitoVit E (MF-E) mice
(Mean values with their standard errors, analysis of five images per mouse and two mice per group)
LF-C LF-E MF-C MF-E ANOVA (P )*
Mean SEM Mean SEM Mean SEM Mean SEM Diet MitoVit E Diet £ MitoVit E
Number of mitochondria (number/section)
Intermyofibrillar mitochondria 17·7c 3·7 16·3b,c 2·3 5·7a 1·7 7·3a,b 1·1 0·012 0·969 0·566
Subsarcolemmal mitochondria 23·1c 1·7 25·7c 2·7 3·0a 0·6 15·9b 0·1 ,0·001 0·009 0·035
Average of mitochondrial size (mm2)
Intermyofibrillar mitochondria 0·123 0·023 0·126 0·056 0·076 0·018 0·104 0·006 0·342 0·651 0·716
Subsarcolemmal mitochondria 0·305a,b 0·016 0·397b 0·015 0·125a 0·003 0·387b 0·113 0·172 0·037 0·212
a,b,c Mean values within a row with unlike superscript letters were significantly different (P,0·05).
* Values of ANOVA (P ) are P values for main effects, such as diet, MitoVit E and interaction between diet and MitoVit E in the LF-C, LF-E, MF-C and MF-E groups. There is
no block effect in the ANOVA model because all the mice (n 8) for microscopy are from the same block.
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protected liver mitochondria from Fe/ascorbate-induced oxi-
dative damage by decreasing protein carbonyl(41).
A previous study has found that in a diabetic mouse model
after 16 weeks of HF, high-sucrose feeding, the number and
size of both subsarcolemmal and intermyofibrillar mitochon-
dria in the skeletal muscle decreased along with a significant
increase in ROS production(42). The same study also reported
that mice treated with streptozotocin, a well-known model of
hyperglycaemia-associated oxidative stress without insulin
resistance and obesity, significantly decreased the mitochon-
drial number, whereas N-acetylcysteine treatment of these
streptozotocin mice restored the mitochondrial density, indi-
cating that mitochondrial number and size might be altered
by oxidative stress. In addition, a decrease in mitochondrial
size and number has also been reported in the neurons of
patients with Alzheimer’s disease(43), the pathogenesis of
which has been extensively attributed to mitochondrial oxi-
dative damage and dysfunction(44).
Consistent with this concept, the present results showed
that the MF diet decreased the number of intermyofibrillar
and subsarcolemmal mitochondria in the soleus muscle,
whereas MitoVit E increased the number and size of the sub-
sarcolemmal mitochondria. However, why MitoVit E only has
the effect on the subsarcolemmal but not on the intermyofi-
brillar mitochondria still remains elusive. Combined with
H2O2 production rate data in the gastrocnemius though,
another question arises: why did MitoVit E have no effect on
mitochondrial H2O2 production rate in the gastrocnemius,
but it could still increase the size and number of subsarcolem-
mal mitochondria in the soleus? We could not exclude the
possibility that MitoVit E might affect the subsarcolemmal
mitochondrial density by some other unknown properties
other than as an antioxidant. Alternatively, this question
could also have to do with the different fibre types in the
two muscles (red oxidative soleus v. white glycolytic gastro-
cnemius). The precise mechanism still remains unclear until
the effects of MitoVit E on the mitochondrial density in the
gastrocnemius and the mitochondrial H2O2 production rate
in the soleus muscle are investigated in the future.
Clinically, one of the keys to success in the diagnosis and
management of those oxidative damage-induced metabolic
disorders is the utilisation of those easily accessible plasma-
and urine-based biomarkers for the objective assessment of
oxidative stress and response to therapeutics.
In the present study, urinary isoprostane was used as a sys-
tematic oxidative stress marker. To our knowledge, the effect
LF-C





























Fig. 2. Representative transmission electron microscopic images (original magnification, 4000 £ ) of subsarcolemmal and intermyofibrillar mitochondria from the
soleus muscle of low-fat diet-fed mice receiving drug vehicle (LF-C), low-fat diet-fed mice receiving mitochondria-targeted vitamin E derivative (MitoVit E) (LF-E),
medium-fat diet-fed mice receiving drug vehicle (MF-C) and medium-fat diet-fed mice receiving MitoVit E (MF-E). Arrows indicate mitochondria.
Table 3. Decrease in urinary isoprostane from low-fat diet-fed mice receiving drug vehicle (LF-C), low-fat diet-fed mice receiving mitochondria-targeted
vitamin E derivative (MitoVit E) (LF-E), medium-fat diet-fed mice receiving drug vehicle (MF-C) and medium-fat diet-fed mice receiving MitoVit E
(MF-E)*
(Mean values with their standard errors for six mice per group)
LF-C LF-E MF-C MF-E ANOVA (P )†
Mean SEM Mean SEM Mean SEM Mean SEM Block Diet MitoVit E Diet £ MitoVit E
Decrease in urinary isoprostane (mmol/mol creatinine)
Week 6 36·38b 4·59 62·98c 7·34 21·40a 3·66 38·41b 3·96 0·339 ,0·001 ,0·001 0·321
Week 7 34·66a 5·79 60·86b 7·88 19·82a 4·25 35·36a 3·02 0·093 ,0·001 0·001 0·261
Week 8 34·52a 5·80 59·68b 8·47 21·54a 3·50 30·71a 8·96 0·039 0·003 0·023 0·170
Week 9 35·28a 4·30 57·89b 6·65 22·11a 3·28 35·13a 4·93 0·235 0·001 0·002 0·293
Week 10 28·23a 5·57 57·75b 8·30 19·48a 4·42 32·72a 4·02 0·085 0·005 0·002 0·121
a,b,c Mean values within a row with unlike superscript letters were significantly different (P,0·05).
* Urinary isoprostane was normalised by urinary creatinine, and decrease in urinary isoprostane was calculated by subtracting the levels of urinary isoprostane at weeks 6, 7,
8, 9 and 10 from the baseline level of urinary isoprostane at week 5, respectively.
† Values of ANOVA (P ) are P values for block effect and main effects, such as diet, MitoVit E and interaction between diet and MitoVit E in the LF-C, LF-E, MF-C and
MF-E groups.
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of MitoVit E on plasma or urinary isoprostanes has never been
studied before. However, there are several studies available in
the literature for the effect of non-targeted vitamin E on the
isoprostanes, even though their results are not consistent.
Both a-tocopherol and mixed tocopherol supplementation
resulted in reduced plasma isoprostanes but did not affect
24 h urinary isoprostanes in patients with type 2 diabetes(45).
However, in the patients with coronary disease, high-dose
a-tocopherol supplementation significantly reduced urinary
isoprostanes(46). By contrast, vitamin E supplementation
failed to decrease urinary isoprostanes in either lean or
obese mice(47).
The present results indicate that MitoVit E decreased urinary
isoprostanes, and its effect was more significant in LF diet-fed
mice than in MF diet-fed mice, which could be attributed to
the fact that the decrease in urinary isoprostane concentration
in the LF-E group was significantly higher than in the other
three groups (LF-C, MF-C and MF-E).
Decrease in antioxidant status leading to the generation of
oxidative stress may play an important role in the pathogen-
esis of oxidative stress-induced metabolic disorders(48).
Indeed, decreased activities of plasma SOD and GPx were
commonly observed in different models of oxidative stress,
whereas antioxidant treatments normalised their activi-
ties(49–51).
Consistently, the present results indicate that the MF diet
significantly decreased plasma SOD and GPx activities and
thus increased plasma H2O2 concentration when compared
with the LF diet. However, in the present study, MitoVit E
only increased the activity of plasma SOD but not the activity
of plasma GPx. Similar observations were found in a lipopoly-
saccharide-induced oxidative stress model in the rat liver(50).
Lipopolysaccharide treatment significantly decreased hepatic
antioxidant enzyme activities such as SOD and GPx, whereas
pre-treatment with resveratrol, a polyphenol with antioxidant
properties abundantly found in red wine, significantly
reversed lipopolysaccharide-induced decrease in SOD activity
but only slightly (and not significantly) improved the lipopoly-
saccharide-induced decrease in GPx activity(50). By contrast, in
the ethanol-induced oxidative stress model, MitoVit E has
been reported to mitigate ethanol-induced suppression of
GPx/glutathione reductase functions, protein expression of
g-glutamylcysteine synthetase and total cellular glutathione
levels(23). Whether MitoVit E might also alter the levels of oxi-
dised/reduced glutathione and g-glutamylcysteine synthetase
in our model is still unknown and needs to be studied in
the future.
In summary, the present study found that MitoVit E did not
affect mitochondrial ATP or H2O2 (when succinate was the
substrate) production rates in both the liver and the gastrocne-
mius. However, MitoVit E increased the number and average
size of the subsarcolemmal, though not the intermyofibrillar,
mitochondria in the soleus muscle of MF diet-fed mice. In
addition, the combination of the LF diet and MitoVit E admin-
istration decreased the urinary isoprostane concentration most
effectively. Finally, MitoVit E increased plasma SOD but not
GPx activity in MF diet-fed mice.
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